The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.

@article{Wagg2014TheEA,
  title={The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.},
  author={Adrian S Wagg and Linda D. Cardozo and Victor W. Nitti and david M. Castro-d{\'i}az and Stephen M Auerbach and Mary Beth Blauwet and Emad Siddiqui},
  journal={Age and ageing},
  year={2014},
  volume={43 5},
  pages={666-75}
}
INTRODUCTION mirabegron is a β3-adrenoceptor agonist developed for the treatment of symptoms of overactive bladder (OAB). As the prevalence of OAB increases with age, a prospective subanalysis of individual and pooled efficacy and tolerability data from three 12-week, randomised, Phase III trials, and of tolerability data from a 1-year safety trial were conducted in order to evaluate the efficacy and tolerability of mirabegron in subgroups of patients aged ≥65 and ≥75 years. METHODS primary… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
28 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Beers Criteria Update Expert Panel . American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults

  • M Imran, AK Najmi, S Tabrez
  • J Am Geriatr Soc
  • 2012

Similar Papers

Loading similar papers…